Overview

A Study on the Treatment Strategy of NVG Secondary to PDR

Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
0
Participant gender:
All
Summary
With the increasing incidence of proliferative diabetic retinopathy (PDR), subsequent neovascular glaucoma (NVG) has become one of the main causes of blindness in PDR patients, and the intraocular pressure of PDR patients with NVG is often stubborn. For these patients, not only is the effect of drugs in lowering intraocular pressure poor, but the results of surgery are often unsatisfactory. Because of its poor prognosis, clinical research for better strategy is of great significance in the current situation. At present, for such patients, a combination of effective control of intraocular pressure and treatment of the primary disease is often used. The purpose of this study was to investigate the clinical effects of preoperative or intraoperative anti-vascular endothelial growth factor (VEGF) drug therapy combined with pars plana vitrectomy (PPV), pan-retinal photocoagulation (PRP), and pressure-reducing valve implantation in patients with NVG secondary to PDR. Furthermore, the changes of neurotrophic factors in the vitreous humor before and after anti-VEGF treatment will be explored.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ruijin Hospital
Treatments:
Bevacizumab
Criteria
Inclusion Criteria:

- male or female patients aged over 18 years diagnosed with type 1 or 2 diabetic
mellitus (DM) confirmed by experienced endocrinologists. Active PDR and NVG was
clinically evident across these patients. The indications to perform surgery included
vitreous hemorrhage or fibrous proliferation in the macular area, together with
uncontrolled intraocular pressure.

Exclusion Criteria:

- (i) coexistent ocular disease that may interfere with visual outcome; (ii) previous
history of vitrectomy or anti-VEGF pharmacotherapy in either eye; (iii) a
macula-involving retinal detachment for >6 months in the study eye; (iv) severe
external ocular infection; (v) usage of anticoagulant or antiplatelet therapy; (vi)
preoperative or postoperative poor diabetes control [serum hemoglobin A1c (HbA1c)
>11.0%]; (vii) uncontrolled systemic diseases, such as hypertension, cardiac diseases
or presenting abnormal coagulation-associated blood diseases.